PKM2 Modulator Combination Therapy for Cancer Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for new treatments and therapies for PKM2-mediated disorders or diseases, particularly in cancer, where existing therapies may not effectively address the metabolic reprogramming and immune evasion mechanisms associated with PKM2 in tumor cells.
Innovation Solution
The development of combination therapies comprising a PKM2-modulating compound, administered with immunological checkpoint inhibitors, kinase inhibitors, or ferroptosis inducers, to target PKM2-mediated cancers by altering the tumor microenvironment and enhancing immunotherapy efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If PKM2 activators are used to treat cancer, then tumor metabolism may be disrupted, but PKM2 is also associated with tumor metabolism in hypoxic environments and immune escape mechanisms
Solution Approach 1:
The patent employs PKM2 activators that specifically alter the functional state of PKM2 enzyme, converting it from a partially active state to a more active state. This parameter change in enzyme activity disrupts the metabolic balance that cancer cells require for survival, particularly in hypoxic environments where PKM2 is upregulated. The activator induces a functional transition that selectively affects cancer cells while sparing normal cells, thereby resolving the contradiction between disrupting tumor metabolism and avoiding harm to hypoxia-adapted tumors.
Solution Approach 2:
The patent uses PKM2 activators as intermediary compounds that mediate between the therapeutic goal of disrupting cancer metabolism and the challenge of tumor adaptation mechanisms. These small molecule activators bind to PKM2 and induce conformational changes that increase its activity, thereby serving as a bridge to restore normal metabolic function in cancer cells without directly targeting the complex hypoxia-response pathways. This intermediary approach allows selective metabolic disruption while avoiding direct confrontation with immune escape mechanisms.
2Reliability
If combination therapies are developed to address PKM2-mediated disorders, then treatment efficacy may be improved, but the complexity of the therapy increases
Solution Approach 1:
The patent combines PKM2 activators with other therapeutic agents in fixed-ratio formulations, merging multiple treatment modalities into a single integrated product. This combining approach addresses PKM2-mediated disorders through multiple mechanisms simultaneously - the activator component targets metabolic reprogramming while the companion agent addresses additional pathological pathways. By merging these therapies into a single fixed-ratio formulation, the patent reduces the operational complexity of combination therapy while maintaining the synergistic benefits of multiple mechanisms of action.
Solution Approach 2:
The patent develops combination therapies that target multiple pathways involved in PKM2-mediated cancer progression. The fixed-ratio formulations are designed to address both the metabolic effects of PKM2 activation and other complementary therapeutic targets, creating a multi-functional treatment regimen. This universal approach allows a single therapy to address multiple aspects of disease pathogenesis, thereby improving treatment efficacy while simplifying the overall therapeutic strategy compared to separate sequential treatments.
Data Source
AI summary
A compound of Structure (I):or a pharmaceutically acceptable salt thereof, alone or in combination with a second therapeutic agent, as well as methods of treating a PKM2-mediated disease or disorder using the same are provided herein.